Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus:A systematic review and meta-analysis
作者机构：Department of Endocrinology and MetabolismThe Second Affiliated Hospital of Lanzhou UniversityLanzhou 730000Gansu ProvinceChina
出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)
年 卷 期：2024年第15卷第7期
页 面：1615-1626页
核心收录：
学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 10[医学]
主 题：Type-1 diabetes mellitus Teplizumab Anti-CD3 monoclonal antibody Insulin Glycated haemoglobin A1c Cpeptide
摘 要：BACKGROUND Islets of Langerhans beta cells diminish in autoimmune type 1 diabetes mellitus(T1DM).Teplizumab,a humanized anti-CD3 monoclonal antibody,may help *** long-term implications on clinical T1DM development,safety,and efficacy are *** To assess the effectiveness and safety of teplizumab as a therapeutic intervention for individuals with *** A systematic search was conducted using four electronic databases(PubMed,Embase,Scopus,and Cochrane Library)to select publications published in peerreviewed journals written in *** odds ratio(OR)and risk ratio(RR)were calculated,along with their 95%*** assessed heterogeneity using Cochrane Q and I2 statistics and the appropriate P *** There were 8 randomized controlled trials(RCTs)in the current meta-analysis with a total of 1908 T1DM patients from diverse age cohorts,with 1361 patients receiving Teplizumab and 547 patients receiving a *** was found to have a substantial link with a decrease in insulin consumption,with an OR of 4.13(95%CI:1.72 to 9.90).Teplizumab is associated with an improved Cpeptide response(OR 2.49;95%CI:1.62 to 3.81)and a significant change in Glycated haemoglobin A1c(HbA1c)levels in people with type 1 diabetes[OR 1.75(95%CI:1.03 to 2.98)],and it has a RR of 0.71(95%CI:0.53 to 0.95).CONCLUSION In type 1 diabetics,teplizumab decreased insulin consumption,improved C-peptide response,and significantly changed HbA1c levels with negligible side *** appears to improve glycaemic control and diabetes management with good safety and efficacy.
维普期刊数据库